The ability of cancer cells to suppress apoptosis is critical for carcinogenesis. The BCL2
family proteins comprise the sentinel network that regulates the mitochondrial or intrinsic …

With the development of precision medicine, molecular targeted therapy has been widely
used in the field of cancer, especially in non-small-cell lung cancer (NSCLC). Epidermal …

Lung cancer shows substantial genetic and phenotypic heterogeneity across individuals,
driving a need for personalised medicine. Here, we report lung cancer organoids and …

Introduction Activating mutations in the epidermal growth factor receptor gene (EGFR)
predict for prolonged progression-free survival in patients with advanced non–small cell …

Background The development of resistance is a problem shared by both classical
chemotherapy and targeted therapy. Patients may respond well at first, but relapse is …

Epidermal growth factor receptor (EGFR) gene mutations (G719X, exon 19
deletions/insertions, L858R, and L861Q) predict favorable responses to EGFR tyrosine …

Epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC) was
first recognized in 2004 as a distinct, clinically relevant molecular subset of lung cancer. The …

Background Personalizing non-small-cell lung cancer (NSCLC) therapy toward oncogene
addicted pathway inhibition is effective. Hence, the ability to determine a more …

Abstract Most advanced Non–Small-cell lung cancers (NSCLCs) with activating epidermal
growth factor receptor (EGFR) mutations (exon 19 deletions or L858R) initially respond to …

Introduction: In non–small-cell lung cancer, an exon 19 deletion and an L858R point
mutation in the epidermal growth factor receptor (EGFR) are predictors of a response to …